Addition Therapeutics
Emily Hallamasek is a skilled research professional with a background in neuroscience and extensive experience in the biotherapeutics and cancer research sectors. Currently serving as a Research Associate II in Hepatocyte Biology at Addition Therapeutics since March 2024, Emily previously held multiple roles at 64x Bio, including Research Associate in Gene Therapy Process and Analytics, as well as in Cell Engineering from January 2023 to January 2024. Additionally, Emily gained valuable experience as a Cancer Research Associate at SageMedic Corp. from June 2022 to November 2022. Emily completed a Bachelor of Science degree in Neuroscience at the University of California, Santa Cruz, in June 2022.
This person is not in any teams
Addition Therapeutics
Addition is transforming genetic medicine by developing RNA-only therapeutics that PRINT any genetic element at specific safe harbor sites